Biden backs Cold-War measures to shore-up medical supply chains
In a recent strategy to combat rising inflation and the cost of living crisis, President Joe Biden has invoked a Cold War-era act to increase investment in a selection of medicines and supplies.
The Biden administration recognises the difficulties in obtaining medical care and medicines for the American population, especially in the current economic climate and the increased cost of drugs.
“We know that prices are still too high for too many things, that times are still too tough for too many families,” Biden stated. “But we’ve made progress."
With the measures introduced with the Inflation Reduction Act and the price capping negotiations, efforts have been made by the US government to improve the situation for patients, and this latest ruling hopes to enable further access to medicine and medical supplies.
This measure, the Defence Production Act, should help to combat issues from disrupted supply chains and drug price increases. The administration includes this act in an announcement of 30 measures designed to increase access to medicine.
The act, backed by President Biden authorises the Department of Health and Human Services to use powers to enable investments in essential medicines. The White House also stated that areas of investment also include "medical countermeasures," encompassing supplies that diagnose, prevent, and treat diseases related to chemical, biological, radiological, or nuclear attacks or incidents.
There are also plans in place to improve the traceability and monitoring of pharmaceutical and industrial supply chains, to measure data, predict, and counter any disruptions that may occur, leading to problems further down the value chain that ultimately impacts patients. One such advancement from the Commerce Department is the development of novel tools and technology to assess potential risks to the supply chain, which they plan to use in conjunction with the Energy Department to monitor the renewable energy resource supply chain.
As the presidential campaigns are gearing up for the next election, polling surveys show that inflation and the economic climate are considered a high concern for the US population, and something for the candidates and parties to consider ahead of the election.
Supply chains have recovered markedly since the COVID-19 pandemic and from politically-driven disruptions, but there is still much work to be done to increase the security and reliability of supply chains and ensure that medical supplies can be accessed by the people in need.
Source: Reuters. Biden invokes Cold War-era measure to boost medical supplies. [Date Accessed 28/11/2023] www.reuters.com/world/us/biden-invoke-cold-war-era-law-boost-medical-supplies-2023-11-27/
Related News
-
News Introducing the Pharmaceutical Sustainability Ecosystem from CPHI
The Sustainability Collective from CPHI unveils the groundbreaking Pharmaceutical Sustainability Ecosystem to drive pharmaceutical knowledge sharing, connection, and collaboration in order to change the face of sustainability in pharmceutical... -
News US Government shutdown leads to the FDA grinding to a halt
The US Congress reached a deadlock after not being able to come to an agreement regarding funding, specifically reaching an impasse when Republicans and Democrats were unable to reach an agreement regarding Obamacare subsidies. The resulting shutdown o... -
News Biosimilars for the better: an expert view from Ecolab
Ecolab expert Renato Azevedo shares his insights on the current state of the biosimilars market in pharmaceuticals, after a high number of biosimilar drug approvals throughout the year confirming the shift of focus in this field. -
News US FDA announces new priority vouchers for accelerated review times
The US FDA announced a new priority program for drug developers – the Commissioner’s National Priority Voucher (CNPV) program aims to enhance the health interests of the US by allowing drug developers to redeem a voucher, shortening th... -
News CPHI Podcast Series: US drug policy – exploring the executive orders
The latest episode of the CPHI Podcast Series provides a timely overview of the recent policy changes in the USA, with President Trump signing excecutive orders to change drug pricing under a 'Most Favoured Nation' scheme.
-
News PhRMA trade association issues comments on Section 232 investigation
The Pharmaceutical Research and Manufacturers of America (PhRMA), an American trade association representing groups in the pharmaceutical industry, issued a letter on May 6, 2026 to the Department of Commerce regarding the Section 232 National Security... -
News Pharmaceutical Packaging Market Prospects: Shifting regional policies
The pharmaceutical packaging industry is experiencing significant transformation in 2025, driven by regulatory changes, supply chain challenges, and sustainability initiatives. The US BIOSECURE Act, passed through the House of Representatives in Septem... -
News The next 15 drugs up for negotiation with Medicare include several blockbusters
By now, everyone is quite familiar with the drug price negotiations taking place between drug companies and the Centres for Medicare & Medicaid Services (CMS) in the USA as part of measures being taken to reduce the cost of drugs for patients, to make ...